
Visceral leishmaniasis (VL) is a neglected tropical disease that results in the loss of an estimated 1 million disability-adjusted life years annually in South East Asia [1]; it is typically fatal if untreated. VL predominantly affects the poorest strata of society and those with limited access to care [2]. The incidence is estimated to be between 146,700 and 282,800 cases per year [3].
Read more »
Post kala-azar dermal leishmaniasis following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) for primary visceral leishmaniasis in Bihar, India
The skin condition post Kala-azar dermal leishmaniasis (PKDL) usually develops following treatment for visceral leishmaniasis (VL), which is caused by the protozoa Leishmania donovani. Although cases of PKDL have been described in patients not previously diagnosed with or treated for VL, up to 10% of patients with VL in the Indian subcontinent go onto develop PKDL following treatment for symptomatic VL [1].
Read more »